The benign treatment-related imaging changes may pose a challenge in appropriate clinical decision making for the neuro-oncologists. The post-treatment changes are usually benign and differ largely in management approach from a progressive tumor. In this study, 304 glioblastoma patients were evaluated retrospectively to study the ability of radiomic analysis to distinguish the post-treatment changes from a truly progressive disease. 3D volumetrics using 3D Slicer 4.3.1 and texture analysis of the lesions were performed. On LOOCV, sensitivity and specificity of 97% and 72% were obtained respectively. We concluded that radiomics can differentiate between the progressive disease and pseudo-progression in glioblastoma patients.